ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

已取消 20 由林发布于 2025/8/2 16:54:14

DOI:10.1182/blood-2022-162249
作者：T. Hughes, Jordi Cortés, N. Takahashi, R. Larson, G. Issa, F. Bombaci, N. Ramscar, S. Kapoor, S. Ifrah, A. Hochhaus
文献类型：期刊论文
补充材料：只需要正文
管理员驳回:超时未应助，系统关闭。如求助信息不完整（标题、DOI、原文链接），可以补充后重新发布求助。

American Society of Hematology (ASH)

Abstract：Objective : To compare the efficacy of asciminib versus investigator-selected 1G or 2G TKI in patients with newly diagnosed Ph+ CML-CP overall, as well as separately for asciminib vs investi

应助信息

2025-08-02

Book学术机器人

2025/8/2 16:54:14 未找到该文献，机器人已退出，请等待人工下载

2025/8/2 16:54:14 Book学术AI机器人收到请求，开始寻找文献

2025/8/2 16:54:14 已向机器人发送请求

2025-08-02

林发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Theoretical Study on Gas-Sensing Mechanisms of Transition Metal-Doped MoS2 for Transformer Oil Dissolved Gases.